[go: up one dir, main page]

CL2011000999A1 - Virus sincicial respiratorio (vsr) vivo atenuado; molecula de acido nucleico que lo codifica; celula recombinante; composicion inmunogenica que lo comprende; y su uso para inducir una respuesta inmune protectora en un paciente contra una infeccion por vsr. - Google Patents

Virus sincicial respiratorio (vsr) vivo atenuado; molecula de acido nucleico que lo codifica; celula recombinante; composicion inmunogenica que lo comprende; y su uso para inducir una respuesta inmune protectora en un paciente contra una infeccion por vsr.

Info

Publication number
CL2011000999A1
CL2011000999A1 CL2011000999A CL2011000999A CL2011000999A1 CL 2011000999 A1 CL2011000999 A1 CL 2011000999A1 CL 2011000999 A CL2011000999 A CL 2011000999A CL 2011000999 A CL2011000999 A CL 2011000999A CL 2011000999 A1 CL2011000999 A1 CL 2011000999A1
Authority
CL
Chile
Prior art keywords
vsr
encodes
induce
nucleic acid
acid molecule
Prior art date
Application number
CL2011000999A
Other languages
English (en)
Inventor
Mary K Yagodich
Michael P Citron
Daniel J Distefano
David L Krah
Xiaoping Liang
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of CL2011000999A1 publication Critical patent/CL2011000999A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
    • C07K14/135—Respiratory syncytial virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/544—Mucosal route to the airways
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18561—Methods of inactivation or attenuation
    • C12N2760/18564—Methods of inactivation or attenuation by serial passage

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Virus sincicial respiratorio (VSR) vivo atenuado; molécula de ácido nucleico que lo codifica; célula recombinante; composición inmunogénica que lo comprende; y su uso para inducir una respuesta inmune protectora en un paciente contra una infección por VSR.
CL2011000999A 2008-11-05 2011-05-04 Virus sincicial respiratorio (vsr) vivo atenuado; molecula de acido nucleico que lo codifica; celula recombinante; composicion inmunogenica que lo comprende; y su uso para inducir una respuesta inmune protectora en un paciente contra una infeccion por vsr. CL2011000999A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19832708P 2008-11-05 2008-11-05

Publications (1)

Publication Number Publication Date
CL2011000999A1 true CL2011000999A1 (es) 2012-07-20

Family

ID=41527812

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011000999A CL2011000999A1 (es) 2008-11-05 2011-05-04 Virus sincicial respiratorio (vsr) vivo atenuado; molecula de acido nucleico que lo codifica; celula recombinante; composicion inmunogenica que lo comprende; y su uso para inducir una respuesta inmune protectora en un paciente contra una infeccion por vsr.

Country Status (19)

Country Link
US (1) US9011876B2 (es)
EP (1) EP2346990B1 (es)
JP (2) JP5016731B2 (es)
KR (1) KR20110063863A (es)
CN (1) CN102272295A (es)
AU (1) AU2009311287C1 (es)
BR (1) BRPI0921424A2 (es)
CA (1) CA2742086A1 (es)
CL (1) CL2011000999A1 (es)
CO (1) CO6362047A2 (es)
EC (1) ECSP11011033A (es)
IL (1) IL212437A0 (es)
MA (1) MA32878B1 (es)
MX (1) MX2011004719A (es)
PE (1) PE20110394A1 (es)
RU (1) RU2011122615A (es)
TN (1) TN2011000182A1 (es)
WO (1) WO2010053883A1 (es)
ZA (1) ZA201103259B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2011122615A (ru) * 2008-11-05 2012-12-20 Мерк Шарп Энд Домэ Корп. Живой аттенуированный респираторно-синцитиальный вирус
US20140242669A1 (en) * 2011-08-18 2014-08-28 Ycine Llc Production of infectious rna viruses in yeast
EP2752199A4 (en) 2011-08-29 2015-04-29 Univ Tokushima RSV MUCOSA VACCINE
US9957486B2 (en) 2013-02-08 2018-05-01 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Attenuation of human respiratory syncytial virus by genome scale codon-pair deoptimization
AU2014239583B2 (en) 2013-03-14 2020-07-02 Children's Healthcare Of Atlanta, Inc. Recombinant RSV with silent mutations, vaccines, and methods related thereto
US10369213B2 (en) 2013-10-16 2019-08-06 Merck Sharp & Dohme Corp. Thermostable respiratory synctial virus (RSV) vaccine compositions
WO2015057540A1 (en) 2013-10-16 2015-04-23 Merck Sharp & Dohme Corp. Method of microwave vacuum drying spherical-shaped pellets of biological materials
WO2017030997A1 (en) * 2015-08-14 2017-02-23 Research Institute At Nationwide Children's Hospital Respiratory syncytial virus having altered ns1 protein function and related materials and methods
WO2017075125A1 (en) 2015-10-29 2017-05-04 Emory University Chimeric RSV, Immunogenic Compositions, and Methods of Use
EP3515930A1 (en) 2016-09-23 2019-07-31 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Vaccine candidates for human respiratory syncytial virus (rsv) having attenuated phenotypes
TW202228779A (zh) 2017-03-01 2022-08-01 英商梅迪繆思有限公司 抗rsv單株抗體配製物
WO2019055768A1 (en) * 2017-09-15 2019-03-21 Ohio State Innovation Foundation VACCINES AND METHODS OF MAKING AND USING VACCINES FOR THE PREVENTION OF SYNCYTIAL RESPIRATORY VIRUS (RSV) INFECTIONS
TW202535439A (zh) * 2023-11-17 2025-09-16 美商賽諾菲巴斯德公司 海藻糖疫苗調配物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997038138A1 (en) * 1996-04-04 1997-10-16 The Regents Of The University Of Michigan Attenuated respiratory syncytial virus
JP2002507408A (ja) 1998-03-26 2002-03-12 アメリカン・サイアナミド・カンパニー 麻疹ウイルスもしくはヒト呼吸合胞体ウイルスサブグループｂの弱毒化の原因である突然変異
JP2003530073A (ja) 1999-07-09 2003-10-14 アメリカ合衆国 弱毒化されたヒト−ウシキメラ呼吸器合胞体ウィルスワクチンの製造
WO2004028478A2 (en) 2002-09-27 2004-04-08 Medimmune Vaccines, Inc. Functional mutations in respiratory syncytial virus
JP4783726B2 (ja) * 2003-03-28 2011-09-28 メディミューン，エルエルシー 呼吸器合胞体ウイルスサブグループｂ株９３２０に関連する組成物および方法
CN101646768A (zh) * 2007-02-07 2010-02-10 生物载体株式会社 减毒负链rna病毒
RU2011122615A (ru) * 2008-11-05 2012-12-20 Мерк Шарп Энд Домэ Корп. Живой аттенуированный респираторно-синцитиальный вирус

Also Published As

Publication number Publication date
WO2010053883A1 (en) 2010-05-14
TN2011000182A1 (en) 2012-12-17
AU2009311287A1 (en) 2010-05-14
EP2346990B1 (en) 2016-01-06
JP2012507302A (ja) 2012-03-29
EP2346990A1 (en) 2011-07-27
RU2011122615A (ru) 2012-12-20
ZA201103259B (en) 2012-01-25
PE20110394A1 (es) 2011-06-22
US20110212130A1 (en) 2011-09-01
JP2011250798A (ja) 2011-12-15
MX2011004719A (es) 2011-05-31
JP5016731B2 (ja) 2012-09-05
KR20110063863A (ko) 2011-06-14
BRPI0921424A2 (pt) 2016-01-05
AU2009311287B2 (en) 2013-02-07
MA32878B1 (fr) 2011-12-01
AU2009311287C1 (en) 2015-02-19
IL212437A0 (en) 2011-06-30
US9011876B2 (en) 2015-04-21
CA2742086A1 (en) 2010-05-14
ECSP11011033A (es) 2011-12-30
CN102272295A (zh) 2011-12-07
CO6362047A2 (es) 2012-01-20
JP5743794B2 (ja) 2015-07-01

Similar Documents

Publication Publication Date Title
CL2011000999A1 (es) Virus sincicial respiratorio (vsr) vivo atenuado; molecula de acido nucleico que lo codifica; celula recombinante; composicion inmunogenica que lo comprende; y su uso para inducir una respuesta inmune protectora en un paciente contra una infeccion por vsr.
EA201270063A1 (ru) Рекомбинантные антигены pcb
CL2013002933A1 (es) Composicion inmunogenica de reovirus de peces (prv) que comprende acido nucleico del prv; polipeptido; uso de la composicion inmunogenica que sirve para tratar afecciones de infeccion por prv en un animal
EA201070794A1 (ru) Рекомбинантные антигены rsv
BR112012003064A2 (pt) anticorpos contra vírus sincicial respiratório (rsv) humano e métodos de uso
AR096113A1 (es) Polipéptidos f de prefusión del virus sincicial respiratorio (rsv) solubles y estabilizados
CY1117757T1 (el) Τροποποιημενες πρωτεϊνες rsv f και μεθοδοι χρησης τους
MX375202B (es) Composiciones adyuvantes novedosas.
EA201190327A1 (ru) Новые конструкции белка вируса папилломы человека (hpv) и их применение в предупреждении заболевания, вызываемого hpv
PH12015500092A1 (en) Compositions for immunising against staphylococcus aureus
BR112012033767A2 (pt) processo para produzir um vírus de interesse, para remover um agente adventício, e para remover um agente adventício, vírus,e, composição imunogênica ou vacina.
BRPI0920026A2 (pt) método de tratamento de infecção pulmonar, composição farmacêutica e respectivos usos.
CO6710913A2 (es) Uso de ácido lipasa lisosomal para tratar la deficiencia de ácido lipasa lisosomal en pacientes
PL2331128T3 (pl) Kompozycja zawierająca chitozan do doocznego podawania szczepionki (szczepionek) ptakom
CL2007002710A1 (es) Formulacion inmunogenica que confiere proteccion contra la infeccion o patologia causada por el virus respiratorio sincicial (vrs) que comprende una cepa recombinante atenuada de mycobacterium; y uso de la formulacion inmunogenica para preparar una vacuna para prevenir, tratar o atenuar infecciones del vrs.
WO2010053610A3 (en) Stable anthrax vaccine formulations
BRPI0812317A2 (pt) Sais de ácido etilenodiamina dissuccínico, composição contendo os ditos sais, uso e método de preparação destes.
BRPI0912021A2 (pt) composição padronizada, método de fabricação e uso na resolução de infecção por vírus de rna
WO2011002422A3 (en) Solubility enhancing pharmaceutical formulation
UA110505C2 (ru) Імуногенні композиції bordetella bronchiseptica
MX2013003245A (es) Vacuna contra virus de diarrea viral de bovinos.
WO2011112906A3 (en) Novel immunogens and methods for discovery and screening thereof
EP2162151A4 (en) LIVING WEARED ANTIGEN MARKED VACCINE AGAINST CLASSIC PIGGER
ATE503491T1 (de) Verbesserte anthraximpfstoffe und abgabeverfahren
EA201290319A1 (ru) Применение источника l3 и/или l5 в качестве вакцины или диагностического средства для паразитарного заболевания